Future prospects for treatment of hemoglobinopathies.

AUTOR(ES)

Stamatoyannopoulos, J A

RESUMO

Strategies for the treatment of sickle cell anemia and beta-thalassemia are founded on the knowledge that these disorders result from structural or functional defects in an adult gene for which an intact fetal counterpart exists. During the past decade, several pharmacologic agents have been investigated for their potential to ameliorate sickle cell anemia and beta-thalassemia by increasing the synthesis of fetal hemoglobin in adults. Progress in understanding globin gene regulation is now being combined with advances in retrovirus-mediated gene transfer, and the once-distant goal of providing gene therapy for hemoglobinopathies is rapidly approaching reality.

Documentos Relacionados

• The Hemoglobinopathies. Techniques of Identification: Clinical and Biochemical Analysis, Vol. 6
• Versatility of Aminoglycosides and Prospects for Their Future
• Pathophysiology and Treatment of Heart Failure with Preserved Ejection Fraction: State of the Art and Prospects for the Future
• Symposium on Energy for the Future—Problems and Prospects
• Lung cancer: Current Status and Prospects for the Future